FDA Introduces New Pathway to Accelerate Personalized Gene Editing

Published on Endpoints News

The FDA has unveiled a new “plausible mechanism pathway” to speed access to personalized gene editing therapies, inspired by the Baby KJ case. The approach aims to support rare disease treatment by allowing alternative trial designs while maintaining regulatory oversight.

👉 Read the full article: FDA unveils new path to speed personalized therapies, inspired by Baby KJ

Disclaimer

Images used are for illustrative purposes only and do not depict actual persons, products, or facilities. For full detail, refer to the original article via the provided link. SSCTR does not provide medical advice, and the views expressed are for educational purposes only.